Evaluation of Temozolomide in a SCID Mouse Model of Human B-Cell Precursor Leukemia

References

• Stevens M F, Hickman J A, Langdon S P, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson N W, Slack J A, et al. Antitumor activity and pharmacokinetics in mice of 8‐carbam‐oyl‐3‐methyl‐imidazo[5,1‐d] 1,2,3,5‐tetrazin‐4(3H)‐one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47: 5846–52
   PubMed Web of Science ®Google Scholar
• Stevens M F, Newlands E S. From triazines and triazenes to temozolomide. Eur J Cancer 1993; 29A: 1045–7
   PubMed Web of Science ®Google Scholar
• Tsang L L, Quarterman C P, Gescher A, Slack J A. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3‐methyl‐(triazen‐l‐yl) imidazole‐4‐carboxam‐ide. Cancer Chemother Pharmacol 1991; 27: 342–6
   PubMed Web of Science ®Google Scholar
• Tentori L, Graziani G, Gilberti S, Lacal P M, Bonmassar E, D'Atri S. Triazene compounds induce apoptosis in 06‐alky‐lguanine‐DNA alkyltransferase deficient leukemia cell lines. Leukemia 1995; 9: 1888–95
   PubMed Web of Science ®Google Scholar
• Uckun F M, Gajl‐Peczalska K J, Kersey J H, Houston L L, Vallera D A. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B‐lineage acute lymphoblastic leukemia. J Exp Med 1986; 163: 347–68
   PubMed Web of Science ®Google Scholar
• Uckun F M. Immunotoxins for the treatment of leukaemia. Br J Haematol 1993; 85: 435–8
   PubMed Web of Science ®Google Scholar
• Uckun F M, Manivel C, Arthur D, Chelstrom L M, Finnegan D, Tuel Ahlgren L, Irvin J D, Myers D E, Gunther R. In vivo efficacy of B43 (anti‐CD19)‐pokeweed antiviral protein immunotoxin against human pre‐B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1992; 79: 2201–14
   PubMed Web of Science ®Google Scholar
• Waddick K G, Myers D E, Gunther R, Chelstrom L M, Chan‐dan‐Langlie M, Irvin J D, Turner N, Uckun F M. In vitro and in vivo antileukemic activity of B43‐pokeweed antiviral protein against radiation‐resistant human B‐cell precursor leukemia cells. Blood 1995; 86: 4228–33
   PubMed Web of Science ®Google Scholar
• Myers D E, Irvin J D, Smith R S, Kuebelbeck V M, Uckun F M. Production of a pokeweed antiviral protein (PAP)‐containing immunotoxin, B43‐PAP, directed against the CD 19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials. J Immunol Methods 1991; 136: 221–37
   PubMed Web of Science ®Google Scholar
• Uckun F M, Reaman G H. Immunotoxins for treatment of leukemia and lymphoma. Leuk Lymphoma 1995; 18: 195–201
   PubMed Web of Science ®Google Scholar
• Uckun F M, Chelstrom L M, Finnegan D, Tuel Ahlgren L, Manivel C, Irvin J D, Myers D E, Gunther R. Effective immu‐nochemotherapy of CALLA+C mu+ human pre‐B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti‐CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 1992; 79: 3116–29
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Non‐parametric estimation from incomplete observations. J Amer Stat Assoc 1958; 53: 457–81
   Web of Science ®Google Scholar
• Karran P, Bignami M. Self‐destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res 1992; 20: 2933–40
   PubMed Web of Science ®Google Scholar
• Karran P, Bignami M. DNA damage tolerance, mismatch repair and genome instability. Bioessays 1994; 16: 833–9
   PubMed Web of Science ®Google Scholar
• Newlands E S, Stevens M F, Wedge S R, Wheelhouse R T, Brock C. Temozolomide: a review of its discovery, chemical properties, pre‐clinical development and clinical trials. Cancer Treat Rev 1997; 23: 35–61
   PubMed Web of Science ®Google Scholar
• Messinger Y, Yanishevski Y, Avramis V I, Ek O, Chelstrom L, Gunther R, Myers D E, Irvin J D, Evans W FMU. Treatment of human B‐cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43‐PAP with cytosine arabinoside. Clin Cancer Res 1996; 2: 1533–1542
   PubMed Web of Science ®Google Scholar
• Ek O, Reaman G H, Crankshow D L, Chelstrom L, Myers D E, Uckun F M. Therapeutic efficacy of the thymidylate synthetase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti‐CD19)‐PAP in a SCID mouse model of human B‐lineage acute lymphoblastic leukemia. Leukemia & Lymphoma 1998; 28: 509–514
   PubMed Web of Science ®Google Scholar
• Ek O, Gaynon P, Zeren T, Chelstrom L, Myers D E, Uckun F M. Treatment of human B‐cell precursor leukemia in SCID mice by using a combination of the Anti‐CD 19 immunotoxin B43‐PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone and L‐Asparaginase. Leukemia Lymphoma 1998; 31: 143–149
   PubMed Web of Science ®Google Scholar
• Friedman H S, Dolan M E, Pegg A E, Marcelli S, Keir S, Cat‐ino J J, Bigner D D, Schold S C, Jr. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995; 55: 2853–7
   PubMed Web of Science ®Google Scholar
• Plowman J, Waud W R, Koutsoukos A D, Rubinstein L V, Moore T D, Grever M R. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3‐bis(2‐chloroethyl)‐1‐nitrosourea. Cancer Res 1994; 54: 3793–9
   PubMed Web of Science ®Google Scholar
• Woll P J, Crowther D, Johnson P W, Soukop M, Harper P G, Harris M, Brampton M H, Newlands E S. Phase II trial of temozolomide in low‐grade non‐Hodgkin's lymphoma. Br J Cancer 1995; 72: 183–4
   PubMed Web of Science ®Google Scholar